Please login to the form below

Not currently logged in
Email:
Password:

parathyroid hormone

This page shows the latest parathyroid hormone news and features for those working in and with pharma, biotech and healthcare.

FDA rejects Amgen's osteoporosis hope romosozumab

FDA rejects Amgen's osteoporosis hope romosozumab

Tymlos is a parathyroid hormone-related protein (PTHrP) analogue that competes most closely with Eli Lilly's ageing osteoporosis drug Forteo (teriparatide) and could become a $1bn-plus product at peak,

Latest news

More from news
Approximately 1 fully matching, plus 22 partially matching documents found.

Latest Intelligence

  • Pharma deals in June 2015 Pharma deals in June 2015

    The device, which has been tested in the clinic for the delivery of parathyroid hormone in osteoporosis patients, can be programmed to release drug at precise times and on a

  • Deal Watch table for December 2014 Deal Watch table for December 2014

    Collaboration, licence. 581. Opko Health / Pfizer. Long-acting hGH-CTP for growth hormone deficiency in adults and children (p3). ... ZP-PTH (parathyroid hormone 1-34) delivered via microneedle patch system (p2). Licence.

  • Pharma deals during December 2014 Pharma deals during December 2014

    Lilly's second drug delivery-based deal of the month is the $440m licence with Alza spin-out Zosano Pharma for ZP-PTH, a phase II formulation of parathyroid hormone ... which is currently in phase III trials for the treatment of growth hormone deficiency

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics